Bank of New York Mellon Corp Boosts Stock Position in Boston Scientific Corporation $BSX

Bank of New York Mellon Corp raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 1.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,224,797 shares of the medical equipment provider’s stock after buying an additional 191,825 shares during the quarter. Bank of New York Mellon Corp’s holdings in Boston Scientific were worth $1,070,284,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Boston Scientific during the fourth quarter valued at $2,199,395,000. Egerton Capital UK LLP boosted its stake in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Alphinity Investment Management Pty Ltd bought a new position in Boston Scientific in the 4th quarter worth about $252,918,000. Marshall Wace LLP grew its position in Boston Scientific by 30.7% during the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after purchasing an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A bought a new stake in Boston Scientific during the 3rd quarter valued at about $204,812,000. 89.07% of the stock is owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter, adding clinical support to its coronary portfolio and strengthening the bull case for future product growth. FRACTURE IDE Success Adds Clinical Support To Boston Scientific Valuation Case
• Positive Sentiment: The company announced a share buyback, which can support earnings per share and signal management confidence in the business. Why These Three Big Buybacks Are Sending Very Different Signals to Investors (BSX)
• Positive Sentiment: Analysts remain broadly constructive on Boston Scientific’s long-term outlook despite recent share weakness, suggesting the stock may still have support from the Street. Boston Scientific Stock: Is BSX Underperforming the Healthcare Sector?
• Neutral Sentiment: One update said there were no changes to Boston Scientific’s price target, so investor expectations were left unchanged for now. How A Quiet Reset Is Shaping The Boston Scientific (BSX) Investment Story
• Neutral Sentiment: Jim Cramer discussed Boston Scientific among other medical equipment makers, but the coverage did not include a major new catalyst. Jim Cramer Comments On Boston Scientific and Other Medical Equipment Makers
• Negative Sentiment: Wolfe Research downgraded Boston Scientific to Peer Perform, which may have weighed on the stock and reflects more limited upside in the near term. Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform
• Negative Sentiment: Recent commentary also noted that Boston Scientific has underperformed healthcare-sector peers, reinforcing concerns that momentum has weakened even as analysts stay optimistic. Boston Scientific Stock: Is BSX Underperforming the Healthcare Sector?

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BSX. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Leerink Partners cut their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. Finally, BTIG Research restated a “buy” rating and issued a $65.00 price target on shares of Boston Scientific in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $86.79.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.6%

Shares of BSX stock opened at $47.68 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $47.35 and a 12-month high of $109.50. The stock has a market capitalization of $70.86 billion, a P/E ratio of 19.95, a P/E/G ratio of 0.88 and a beta of 0.56. The firm’s 50 day moving average is $59.79 and its 200 day moving average is $78.08.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.